FDA Approves Daraxonrasib, a Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, a new targeted therapy pill for metastatic pancreatic cancer. This approval is considered a significant turning point for a disease historically associated with limited treatment options and poor prognosis. The drug was tested in a global clinical trial, with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine serving as a key participant.